TB-500

What is TB-500?

TB-500 is a synthetic peptide fragment containing the actin-binding active region of thymosin beta-4 (TB4), a 43-amino-acid intracellular peptide present in virtually all mammalian cells. The most commonly synthesized fragment is the 17-amino-acid central segment containing the LKKTETQ active site (amino acids 17 to 23), often acetylated at the N-terminus to form Ac-LKKTETQ. It is used in veterinary medicine for tendon and ligament injuries and as an off-label tissue-repair peptide in adult research settings.

The molecule is commonly confused with thymosin alpha-1, an immune modulator marketed as Zadaxin. The two share the "thymosin" name from their original isolation from thymic extract but are otherwise unrelated. Thymosin alpha-1 has 28 amino acids and acts as an immune modulator. Thymosin beta-4 has 43 amino acids and acts as a tissue-repair peptide. TB-500 specifically refers to the synthetic fragment of TB4 rather than the full-length parent peptide.

Most research on full-length thymosin beta-4 has been conducted by RegeneRx Biopharmaceuticals under development codes RGN-352 (intravenous, cardiac and neurological), RGN-137 (topical, wound healing), and RGN-259 (ophthalmic, dry eye). Research on the truncated TB-500 fragment has been more limited in formal pharmaceutical development and dominated by veterinary use, particularly in equine sports medicine.

Mechanism of Action

TB-500 acts on intracellular actin dynamics. Actin is the structural protein that forms the cellular cytoskeleton and drives cell movement, division, and shape change. The TB4 fragment binds G-actin (the monomeric form) and prevents it from polymerizing into F-actin (the filamentous form) prematurely. This regulation of actin pools allows cells to rapidly mobilize their cytoskeleton when migration is required, which is the central function in wound healing.

The downstream effects documented in animal models include three main components.

Cell migration to injury sites. TB-500 promotes the movement of keratinocytes, endothelial cells, fibroblasts, and progenitor cells toward damaged tissue. This is the mechanism behind the accelerated wound closure reported in rodent and rabbit wound-healing models (Malinda et al., 1999).

Angiogenesis. New blood vessel formation through endothelial cell recruitment and proliferation. Healing tissue needs new blood supply, and TB-500 supports this part of the cascade.

Anti-inflammatory effects. Reduced expression of pro-inflammatory cytokines and modulation of immune cell recruitment at injury sites. The 2010 review by Sosne and colleagues documented this across multiple model systems.

Animal data on cardiac repair has been the most striking. Bock-Marquette et al. (Nature, 2004) reported that TB4 administration after experimental myocardial infarction reduced infarct size, improved cardiac function, and activated cardiac progenitor cells in mouse models. The cardiac effects appear to be mediated through both the actin-binding mechanism and through specific signaling pathways that promote epicardial progenitor cell mobilization.

The Human Evidence Base

Human clinical-trial data on full-length thymosin beta-4 (the parent compound, not specifically TB-500) is limited to early-phase trials.

Dry eye and ophthalmic indications. RegeneRx developed RGN-259 (topical TB4) through Phase 2/3 trials for dry eye disease. Results have been mixed, with some endpoints showing improvement in tear production and corneal staining. No FDA approval has resulted from the program.

Cardiac repair. A small Phase 1 trial of intravenous full-length TB4 in post-MI patients evaluated safety and tolerability. The trial was not powered for efficacy. Phase 2 was not pursued at the scale needed for registration.

Wound healing. Topical RGN-137 was tested in epidermolysis bullosa and venous stasis ulcers. The clinical-trial data is small and inconclusive.

TB-500 specifically (the truncated fragment). No published Phase 2 or Phase 3 trial in humans uses the synthetic TB-500 fragment as the test compound. The fragment has been studied in cell culture (fibroblast wound-healing assays) and in equine subjects (the racing application). Human use of TB-500 is by extrapolation from full-length TB4 trials and from veterinary experience.

The structural problem with the TB-500 literature is the gap between the parent peptide (TB4) and the synthesized fragment (TB-500). The published animal cardiac and wound-healing data uses full-length TB4. Most human supplementation uses the 17-amino-acid fragment. Whether the fragment reproduces the full peptide's effects, particularly the cardiac progenitor cell mobilization seen with TB4, has not been directly tested in published human studies.

Veterinary Use and Equine Doping Control

The most extensive real-world experience with TB-500 comes from equine sports medicine. The peptide has been used in racehorses for tendon and ligament injuries since the early 2000s. Reported uses include superficial digital flexor tendon (SDFT) injuries, suspensory ligament damage, and post-surgical recovery.

Veterinary literature documents measurable healing improvements in horses within 2 to 4 weeks of loading protocols. The angiogenic and cell-migration effects are particularly relevant to equine tendon repair, since tendons are poorly vascularized structures that heal slowly with conservative therapy.

The performance-enhancing potential of TB-500 in racehorses led the Federation Equestre Internationale (FEI) and multiple racing authorities to ban thymosin beta-4 in competition horses. The Ho et al. 2012 paper in Journal of Pharmaceutical and Biomedical Analysis established a validated LC-MS method for detecting TB-500 metabolites in equine urine and plasma. The method has been used in racing jurisdictions worldwide since.

The equine veterinary experience represents the largest "real-world" dataset on TB-500 administration. It is not directly translatable to human medicine, but it provides observational evidence on dosing, tolerability, and apparent tissue-repair effects.

Dosing Reporting

No standardized human dosing protocol exists for TB-500. Published human pharmacokinetic data on the 17-amino-acid fragment is absent. Three separate evidence streams feed adult research-use practice: full-length TB4 clinical trials, equine veterinary protocols, and uncontrolled adult off-label reports. They do not translate cleanly to each other, and the resulting protocols rest on extrapolation from animal work and observational use rather than controlled human trial data.

Full-Length TB4 Clinical Trials

RegeneRx Biopharmaceuticals conducted Phase 1 dose-escalation work on intravenous full-length thymosin beta-4 (RGN-352) in healthy adults and in post-myocardial-infarction patients. Single-dose escalation tested ranges of approximately 42 mg to 1260 mg by short IV infusion without dose-limiting toxicity, and the subsequent Phase 2 cardiac repair trial used multiple-dose intravenous administration. These doses apply to the full 43-amino-acid peptide. The molecular weight gap to the truncated TB-500 fragment is about a factor of five, so direct mg-for-mg translation is not appropriate. Topical RGN-137 in wound-healing trials used 0.03 percent and 0.1 percent gel formulations applied to the affected area. RGN-259 in dry-eye studies used a 0.1 percent ophthalmic solution dosed four to six times daily.

Equine Veterinary Protocols

The largest real-world dosing dataset comes from racehorse tendon and ligament rehabilitation, where TB-500 has been used continuously since the early 2000s. Published veterinary protocols typically administer 10 mg per dose by intramuscular or subcutaneous injection. The standard schedule is once weekly for a loading phase of 4 to 6 weeks, then tapered to a maintenance interval of 2 to 4 weeks. Equine bodyweights range 400 to 550 kg. That puts the per-kilogram dose at roughly 0.02 mg/kg in horses. Adult off-label human protocols typically work out to less than 0.1 mg/kg, which is higher on a weight-adjusted basis than the equine standard. The equine work is the closest thing to a controlled-environment dosing dataset, although the species gap is substantial.

Adult Off-Label Research-Use Protocols

Off-label adult research-use protocols circulating in research-chemical communities typically describe a loading phase of 5 mg administered subcutaneously twice weekly for 4 to 6 weeks, followed by maintenance doses of 2 to 5 mg every 2 to 4 weeks. The peptide is reconstituted in bacteriostatic water and rotated across injection sites. No controlled human pharmacokinetic study supports these doses, this frequency, or this duration. Half-life estimates for full-length TB4 indicate rapid plasma clearance with extended tissue retention through actin binding, which is the published basis for the infrequent dosing schedules used in equine work and adopted into adult off-label use. The data ends there. The most honest summary is that adult research-use TB-500 dosing is extrapolated from equine veterinary practice and uncontrolled observational reports, not from human trials. Any specific number that circulates in adult research-use communities should be read with that caveat attached.

Safety Profile From Available Data

The published safety record for TB-500 is largely descriptive. Veterinary use across thousands of horses over two decades has not flagged dose-limiting toxicity at the doses used. Human Phase 1 trials of full-length TB4 (not the TB-500 fragment specifically) have not reported serious adverse events at the doses and durations tested.

Expected adverse events based on mechanism and limited clinical experience include:

Injection-site reactions. Redness, mild discomfort, and transient swelling at subcutaneous injection sites. Generally mild and self-limited.

Mild fatigue or lethargy. Some users report subjective fatigue during the first week of dosing. Mechanism unclear.

Theoretical cancer concerns. Both the angiogenic effect (supporting new blood vessel formation) and the cell-migration effect have theoretical relevance to tumor growth and metastasis. Patients with active or recent malignancy should approach TB-500 with that mechanistic flag in mind. No clinical signal has been documented, but the human trials have been too small and too short to characterize this risk.

Active inflammation or infection. The anti-inflammatory mechanism may interact with normal infection response. Use during active infection is generally avoided.

The FDA Category 2 designation reflects the small published human safety database combined with theoretical mechanistic concerns. The agency is saying the evidence is insufficient to support compounding, not that documented harm has occurred.

Regulatory and Compounding Status

TB-500 was added to the FDA Category 2 bulks list under Section 503A on September 29, 2023, under the formal name "Thymosin Beta-4 Fragment (LKKTETQ)." Category 2 status prohibits 503A and 503B compounding pharmacies from preparing the compound for patient use. The FDA cited insufficient safety data and efficacy evidence as the basis for restriction.

The compound is one of those scheduled for reconsideration at the PCAC meeting on July 23 and 24, 2026. Without a substantial increase in published human safety data since 2023, a Category 1 recommendation is unlikely. The most plausible outcomes are continued Category 2 status or referral for additional review.

TB-500 has no FDA approval for any human indication. There is no EMA approval, no MHRA approval, and no marketing authorization in any major regulatory jurisdiction. The full-length TB4 programs at RegeneRx have not resulted in approved products.

TB-500 is on the WADA Prohibited List under section S2 (Peptide Hormones, Growth Factors, Related Substances, and Mimetics). Use in competitive sport is a doping violation in-competition and out-of-competition. The compound is also banned in equine racing under jurisdiction-specific anti-doping rules.

TB-500 vs BPC-157

The most common comparison in adult tissue-repair settings is between TB-500 and BPC-157. The two peptides share regulatory positioning (both on FDA Category 2, both on WADA Prohibited List, both used in similar contexts) but work through different mechanisms.

BPC-157 acts primarily through nitric oxide modulation, VEGFR2 upregulation, and growth-factor receptor pathways. Its strongest evidence base is in animal models of soft-tissue injury and gastrointestinal repair. Three small published human studies. No Phase 3 trials.

TB-500 acts through actin binding and cell migration. Its evidence base is dominated by animal cardiac data and equine veterinary use. The published full-length TB4 human data is limited to early-phase trials in ophthalmic, cardiac, and wound-healing indications.

The two peptides are often stacked in adult research settings under the rationale that they act through complementary mechanisms. No published clinical trial has tested the combination specifically. The stacking practice is supported by veterinary experience and animal-model logic rather than human-trial evidence.

For practical purposes, both sit in the same evidence and regulatory category: preclinical-dominant, restricted from compounding, banned in sport. Neither has an FDA-approved indication, and neither has a registered Phase 3 trial in any human use case. A stabilized BPC-157 analog, Pentadeca Arginate, is often discussed in the same circles for its improved pharmacokinetic profile.

What Comes Next

The PCAC vote in July 2026 will determine whether TB-500 returns to legal compounding in the United States. Without new Phase 1 or Phase 2 human safety trials, the published evidence base is unlikely to change meaningfully before the committee meets. The most likely future for TB-500 is continued Category 2 status or referral for additional review. Larger Phase 2/3 trials of full-length TB4 in dry eye, cardiac repair, or wound healing could shift the regulatory calculus by establishing human safety data that compounders could reference. None of those programs is currently in active Phase 3 development.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.